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Abstract
We present an approach to association studies involving a dozen or so ‘response’ variables and
a few hundred ‘explanatory’ variables which emphasizes transparency, simplicity, and protection
against spurious results. The methods proposed are largely non-parametric, and they are system-
atically rounded-off by the Benjamini-Hochberg method of multiple testing. An application to the
detection of associations between risk factors of heart disease and genetic polymorphisms using
the REGRESS dataset provides ample illustration of our approach. Special attention is paid to
book-keeping and information-management aspects of data analysis, which allow the creation of
an informative and reasonably digestible ‘map of relationships’—the end-product of an association
study as far as statistics is concerned.
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1 Introduction
One of the most common statistical questions arising in epidemiologic re-
search is whether two or more characteristics or ‘variables’ that can be ob-
served in individuals of a given population are associated. By saying that two
or more variables are associated we mean that their ‘underlying’ joint dis-
tribution does not factorize into the product of their marginal distributions,
and, accordingly, producing evidence of an association requires sampling from
the population in question and assessing the relationship between joint and
marginal empirical distributions in terms of a statistical test. To give an
example, if one of the variables is HDL (high-density lipoprotein) cholesterol
level and the other is the variant of a single nucleotide polymorphism, so that
an individual has one of three genotypes, then a statistical test of associa-
tion may be based on the comparison of the three distributions of HDL in
the population strata of genotypes 1, 2 or 3, and the evidence against the
hypothesis of no association may be weighed by means of the p-value—the
probability that a sample drawn from the same population would, were there
no association, yield a discrepancy between the three distributions bigger
than or as big as the discrepancy actually observed.
The aim of epidemiologic research is often to establish causal relation-
ships between variables as a means of identifying the main causes of a disease,
and this is a long way from the mere detection of associations. For instance,
even if an association between HDL and a polymorphism is established be-
yond reasonable doubt, it may very well be that the polymorphism is asso-
ciated with another polymorphism that regulates the synthesis of a protein
which in turn influences HDL, and it may be the identification of the latter
association that turns out to be useful in developing new treatments for heart
disease. Thus, as Rothman (2002) insists, epidemiology is “more than the
application of statistical methods to the problems of disease occurrence and
causation”. On the other hand, the search for associations is usually a crucial
first step in an epidemiologic investigation. This is especially the case in the
study of so-called ‘complex diseases’ such as diabetes, heart disease, many
forms of cancer, and neurological diseases—diseases attributable to a combi-
nation of several genetic and environmental factors—where, understandably,
the starting point of the investigation often amounts to a collection of more
or less speculative hypotheses about a large number of phenotypic and geno-
typic variables and further progress rests partly on a reliable picture of the
statistical associations between those variables. Once good evidence is ob-
tained about a number of associations, epidemiologic research will, ideally,
proceed with the sketch of a provisional biomedical theory explaining the
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causes of the disease and the formulation of hypotheses that can be used to
test it, and eventually modify it in later stages, with new data (see p. 697 of
Willett (2002) for specific examples). Often, as pointed out on p. 700 of Rees
(2002), medical treatment is suggested by associations between variables long
before any mechanistic explanation of the disease is advanced, and it is the
effectiveness of the treatment that subsequently helps building a satisfactory
theory. In any case, however long and tortuous the research path may be
starting from the investigation of the first associations, and irrespective of
whether it will eventually lead somewhere, it is clear that wrong tracks indi-
cated by false positive results should be avoided; for if it is generally difficult
to build a biomedical theory it is certainly more difficult to build a valid one
out of the wrong elements. This is why the detection of genuine associations
by means of statistical methods, despite being only a tiny, first step towards
the biomedical elucidation of a disease, plays such an important role in the
epidemiologic research of complex diseases (see also p. 697 of Willett (2002)).
Unfortunately, detecting associations between variables is not a com-
pletely straightforward task; the existence of a plethora of contradicting,
irreproducible or downright spurious associations in biomedical science, now
generally acknowledged and partly explained by some (Winkelmann et al.
(2000), Willett (2002), Ioannidis (2005), Goodman and Greenland (2007)),
is perhaps the best illustration of that. Besides scientific malpractices, there
are at least three properly methodological or statistical (despite the fact that
in most cases associations are tested with standard statistical tests) difficul-
ties inherent to association studies that account for the abundance of false
positive results. First, there is the problem of confounding, on which we will
expand below; this is often responsible for distorting, in both magnitude and
direction, associations between variables, and can even yield spurious results.
Secondly, there is the problem of multiple testing: in studies involving
many tests, the practice of discrediting any null hypothesis whose p-value
is below 0.05 is bound to give rise to many false positives within a single
study.1 Although such practice does not really deserve the qualification of
‘malpractice’ (in contrast to the repeated, unreported testing of hypotheses
until ‘significant’ results are obtained, one of the forms of what may be called
1The best part of Ioannidis’s (2005) argument may be translated into the proposition
that rejecting hypotheses on the basis of a fixed ‘p-value threshold’ necessarily yields many
false positive results.
‘data dredging’) it is becoming difficult to tolerate following the impact of
multiple testing methods, such as Benjamini and Hochberg’s (1995).
Finally, there is the problem of ‘incorrect model specification’. In many
association studies, hypotheses of association are tested within parametric
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regression models which specify a relationship between a ‘response variable’
such as HDL and several ‘explanatory variables’ such as the genotype of
a polymorphism, age, body mass index (BMI), etc. (e.g. Kathiresan et al.
(2007)). The rationale for doing this is that tests based on parametric mod-
els are more powerful than non-parametric tests and that by including other
explanatory variables one simultaneously ‘corrects for confounders’ that may
distort the association between the response and the explanatory variable of
interest and (thanks to the decrease in noise achieved by the incorporation
of greater ‘explanation’) further increases power. Despite the lucid appraisal
of regression models made by some epidemiologists (e.g. Rothman (1986) in
his Chapter 14), this point of view has become so widespread in biomedical
research that it may rightly be called a paradigm.2 And yet, in many cases—
especially in cases where there are more than just a couple of variables and
only a few hundreds of patients—the assumption that a regression model
describes the relationship between response and explanatory variables suffi-
ciently well so as to allow a reliable investigation of the association between
the response and a particular explanatory variable is problematic.
In this work we propose an approach to association studies involving
relatively large numbers of variables that obviates, or at least mitigates, the
problems now described, and illustrate its application to the detection of
associations between risk measures of heart disease and genetic polymor-
phisms. Our starting point is the assumption that the first aim of an asso-
ciation study—or of a ‘low-level association study’—is to detect associations
between a ‘small’ set of response variables and a ‘large’ set of explanatory
variables—not to quantify or model putative associations, which we regard as
a much more difficult, ‘higher level’ problem to be tackled in later stages when
more concrete hypotheses have been formulated and more refined studies
(e.g. based on more specific population groups) can be set up. The amount of
2According to the experience of the first author, the situation has gone so far that
during the process of reviewing papers one is sometimes asked to justify the use of a simple
analysis based on non-parametric methods—for instance the application of the Wilcoxon-
Mann-Whitney test within population strata—in place of a multivariate analysis based on
a complicated parametric model, when it is the latter rather than the former that requires
justification.
research dedicated to establishing associations between two or more variables
and the theoretical framework provided by some epidemiologists (e.g. Wil-
lett (2002)) justify this basic assumption. The response variables are to be
thought of as risk measures for a certain disease—as for instance HDL choles-
terol and blood pressure are for heart disease—and the explanatory variables
as a set of genotypic and/or phenotypic variables—the genotypes of polymor-
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phisms, age, BMI, etc.—that could influence the response variables and thus
possibly explain the occurrence of the disease.
Despite being based largely on standard statistical methods, the
methodology we suggest contains original elements and departs from the run-
of-the-mill association study in essential points. On the other hand, like most
other approaches to association studies, it is fully based on p-values. Thus,
given the philosophical objections sometimes raised to the use of p-values, it
seems well to observe that the detection of associations by means of multiple
testing methods typically achieves a very concrete purpose: in the case of the
Benjamini-Hochberg method advocated here, it imposes an upper bound on
the so-called false discovery rate and (roughly speaking) still finds as many
genuine associations as is feasible.
Finally, it is important to state one thing that our approach is not: it
is not an approach to prediction, nor to variable selection, nor to both. By
‘prediction’ we mean the activity of guessing the value of a response variable
(HDL levels in a patient, say) on the basis of a set of explanatory variables
(age, BMI, ‘genetic profile’, etc.), by means of a function—the predictor—
relating the latter to the former; by ‘variable selection’ we mean the activity
of selecting the explanatory variables that, used in the predictor, and ac-
cording to a criterion such as ‘mean-squared error’ or ‘probability of correct
classification’, best predict the value of the response variable. Trivially, an
explanatory variable may be associated with a response variable but be prac-
tically useless in guessing its value; and an explanatory variable may be very
accurate in guessing the value of a response variable without there being any
relevant causal relationship between the two. Irrespective of whether a set of
explanatory variables is useful to predict a response variable or is ‘selected’
on the basis of a criterion, establishing an association between the two can
be very useful and remains a legitimate aim. Thus, as pointed out on p. 696
of Willett (2002), the information carried by a single phenotypic variable
‘measured in the clinic’ often subsumes the information provided by several
polymorphisms, which renders the latter practically useless for prediction
purposes; nevertheless, establishing that an association between the pheno-
typic variable and the polymorphisms exists can be crucial in establishing
causality.
Section 2 presents and justifies our approach in more or less formal terms
and, along the way, touches on the subjects of confounding, multiple testing
and incorrect model specification; the Benjamini-Hochberg method, which
is the basis of our approach, is described in Subsection 2.1, and Subsection
2.2 discusses possible pitfalls. The rest of the paper, Section 3, describes
an application to the problem of finding associations between risk measures
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of heart disease and genetic polymorphisms using data from the REGRESS
study (Jukema et al. (1995)).
2 Description and justification of the method
Let us recall the type of association study we have in mind: given a ‘small’
number of response variables of interest—cholesterol levels, blood pressure,
etc.—and a ‘large’ number of explanatory variables—genetic polymorphisms,
age, BMI, etc.—the objective is to look for associations between the response
variables and the explanatory variables and to come up with a ‘map of rela-
tionships’ summarizing the main findings and which can be used to formulate
a theory (no matter how rudimentary) explaining how the response variables
are influenced by (and perhaps influence) some of the explanatory variables.
In this setting, we propose an analysis in four steps. In the first step we
test the association between each pair of response variables, rank the pairs
according to their p-values (which reflect the strength of the associations),
use the ranking to construct a graph—a dendogram obtained by a cluster
analysis method, for example—summarizing the relationship between the re-
sponse variables, and finally pick some of these variables to be used in the
remainder of the analysis.
The purpose of this first step is not to establish causal relationships
between the response variables; this would be virtually impossible using sta-
tistical methods—and certainly cluster analysis methods—alone. Its purpose
is rather to give an overview of the response variables, of the putative rela-
tionships between them, and of the relative strength of the relationships that
are most likely to exist, and eventually to help selecting a smaller set of re-
sponse variables on which to focus. Typically, many of the response variables
are known to be associated, and the interesting response variables have been
fixed in advance. Thus, to exemplify, systolic and diastolic blood pressures
are known to be strongly associated variables, as are age and cholesterol lev-
els, and in a study aiming at detecting genotypes that contribute to heart
disease it would be a matter of course to include risk measures of heart dis-
ease such as HDL and LDL (low density lipoprotein) cholesterol and blood
pressure as response variables; however, if it were found that in a given group
of patients HDL and ‘triglyceride levels’ had a very strong relationship, then
one might consider, for simplicity’s sake, discarding one of these two variables
from the remainder of the analysis. Another purpose of the overview of the
response variables and their relationships obtained in the first step is to help
creating the ‘map of relationships’ in the final stage of the association study.
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In the second step we try to detect associations between each one
of the response variables (fixed in the first step) and the large number of
explanatory variables by means of the Benjamini-Hochberg method, or, in
those cases where this is deemed inapplicable, of the Bonferroni method; see
Subsection 2.1 for a description of these methods. The main concern here is to
avoid false positive results—by fixing an upper bound on the false discovery
rate in the case of the Benjamini-Hochberg method, and on the probability
of at least one false positive result in the case of the Bonferroni method.
For this reason, it is important that the p-values be computed correctly and
accurately. Parametric tests and tests based on asymptotic results yield
numerically accurate p-values, but such p-values can be incorrect because,
strictly speaking, they are computed under the incorrect null distribution;
this is typically the case with t- and F-tests, and with tests on the value of
a parameter in a multiple regression model (e.g. modelling HDL levels as a
function of a polymorphism with age, BMI and sex as explanatory variables).
While it is true that when carrying out a single test one can sometimes
transform variables and/or choose a more appropriate model in order to get
a reliable p-value, in a situation where many tests need to be performed
the possibility that the p-values are biased presents a more serious problem,
if only because the p-values that are of any consequence are usually very
small and a violation of a model’s assumptions typically expresses itself more
seriously ‘in the tails’. Of course, the amount of bias in a multiple testing
procedure due to a bias in the p-values will depend very much on the type of
data at hand, but as a general rule it seems sensible to consider using exact,
non-parametric tests.
One disadvantage of exact, non-parametric tests is that the accurate
calculation of p-values (with a number of decimal places that allows us to
distinguish 0.001, say, from zero), which is usually based on simulation, may
be time consuming; however, given the resources currently available to the
average statistician, this does not appear to be a serious disadvantage.
Perhaps the argument more frequently invoked against the use of non-
parametric tests is that they entail ‘loss of power’—relative, one presumes, to
a test based on a parametric model that fits the data sufficiently well. From a
‘distributional’ point of view—ignoring the potential benefits of correcting for
confounder variables—statistical folklore based on the comparison between
the t-test and the Wilcox-Mann-Whitney test and similar examples suggests
that the purported loss of power is overrated and, in view of the more or
less serious deviations from model assumptions that are likely to occur, often
turns into a gain in power.
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Correcting for confounders can be advantageous in terms of power. This
is obviously the case when a response variable is associated with an explana-
tory variable and the association is direct within one age stratum (say) and
inverse within another, since neglecting age will then dilute the association
in the overall population and consequently decrease power. On the other
hand, it is equally obvious that there can be no theorem stating whether it is
better to account or not account for confounders in general: if the association
between the response and the explanatory variable varies in intensity but has
the same direction across age strata, then we may well be better off, regarding
power of detection, looking at the overall population. Thus it seems sensi-
ble to keep an open mind on the subject of correcting for confounders and
to consider Rothman’s (2002) recommendation of stratifying the population
according to variables thought to distort, and especially invert, associations.
Once strata have been defined, one can carry out independent multiple test-
ing procedures within strata and compute a bound on the false discovery rate
as the sum of the bounds on the false discovery rates within strata; or, alter-
natively, one can compute ‘single p-values’ as functions of the p-values from
individual strata (e.g. using Fisher’s method or by averaging the absolute
values of test statistics across strata), and apply a multiple testing procedure
to these.
Correcting for confounders in a regression model can also increase power,
both relative to an approach that simply ignores confounders and to an ap-
proach that stratifies the population according to confounders—the ‘non-
parametric approach to correcting for confounders’ recommended by Roth-
man (2002) which we have just mentioned. However, one can only hope to
‘correct for confounders’ with a model that is approximately correct, which
brings us back to the objections to parametric models raised four paragraphs
above: if one agrees that biased p-values should be avoided in a multiple
testing problem and that it is generally difficult to assess the bias incurred in
the calculation of many p-values under a parametric model, then one should
at least consider not using tests based on regression models that correct for
confounders. It is interesting to point out that in association studies the in-
corporation of a confounder such as age or BMI in a regression model often
does not account for interactions between the explanatory variable of inter-
est (e.g. a polymorphism) and the confounder (e.g. Kathiresan et al. (2007)),
while one would expect the parameter corresponding to the former to depend
on the values of the latter (for example, we shall see towards the end of our
application in Section 3 that the effect of certain polymorphisms on HDL
is likely to depend on age). This practice is understandable in view of the
number of parameters one would have to have in a model including main ef-
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fects of confounders and enough interactions with the explanatory variable of
interest, but it raises the question of whether regression models can generally
be expected to yield ‘legitimate’ p-values in a multiple testing context.
At this point it is important to state two advantages that our approach
has over the more standard approaches to association studies. In the first
place, the use of non-parametric methods, including the eventual correction
for confounders by stratification, makes the results of the study rather robust
to the particularities of the analyst: for instance, there are only a few ‘right’
non-parametric methods of testing an association, and those few ones are
usually comparable regarding both power and assumptions. This robustness
is obviously helpful in isolating the causes of eventual spurious associations
and inconsistent results. In contrast, an approach based on regression models
leaves so much room for manoeuvre that it is frequently difficult to compare
the results of two independent studies on the same problem.
Secondly, the combination of non-parametric tests with a multiple test-
ing procedure makes the results of the study essentially unique. In particular,
the fact that all associations between a response variable and the explanatory
variables are tested ensures that no ‘non significant’ results are left unreported
and that the evidence in favour of purported associations has been properly
weighed. In contrast, the validity of a study in which only a small subset of
explanatory variables is considered, largely dispensing the need for a multiple
testing method, rests on the assumption that no other explanatory variables
were investigated. Of course, in some studies it makes perfect sense to study
associations between a response variable and a small set of explanatory vari-
ables, but these are ‘high level studies’; in the ‘low level studies’ we consider
here, where there are many more explanatory variables than response vari-
ables, it is unlikely to have each response variable coupled to a small set of
explanatory variables.
To go on with the description of our approach, at the end of the second
step we will have in principle declared significant some of the associations
between the response variables and the explanatory variables; in the third
step we focus on the explanatory variables for which at least one association
with a response has been singled out and try to detect pairwise associations
between them, again using non-parametric tests and a multiple testing pro-
cedure. The associations tested for in the third step are thus conditional on
what was declared significant in the second. One might well consider testing
the pairwise associations between all explanatory variables, but this seems
less interesting for two reasons: first, increasing the number of hypotheses
typically decreases power of detection; secondly, concentrating on the ex-
planatory variables which are likely to be related to the response variables
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will lead to a smaller and more connected ‘map of relationships’, which is
perhaps more helpful as a starting point for building up explanations than a
more inclusive but sparser one.
Finally, in the fourth step we summarize and verify the associations
declared significant in the second or third steps. The simplest and most
faithful summary of the results will be a graph where each node represents
a response variable or a set of explanatory variables and an edge linking two
nodes indicates an association that was declared significant. But in drawing
such a ‘map of relationships’ one should be allowed a certain amount of
freedom to add response variables other than those considered in the second
and third steps and to cluster together explanatory variables that are likely to
be associated with each other and associated with the same response variable,
for example. There is hardly any danger of overinterpreting the findings by
doing this, as edges and clusters are determined by associations that were
declared significant.
Post hoc information concerning possible confounding or ‘effect modi-
fying’ variables may also be added to the graph. Such information can be
gained by verifying the associations, namely by examining the distribution of
a response variable as a function of the relevant explanatory variable across
strata of a third variable thought to influence the direction or intensity of
the association between the response and explanatory variables. In order
to avoid the obvious problems of so-called ‘sub-group analyses’ it is impor-
tant to regard any post hoc observation as tentative and the whole process of
‘verification’ as exploratory—and not to attach too much value to ‘post hoc
p-values’. The recognition that certain apparently correct observations can-
not really be substantiated by means of a p-value does not really neutralize
them; if those observations have been made and can be properly understood
within a biomedical context then they will carry their weight into the next
stage of research.
In order to motivate further this fourth step, and in particular the ‘verifi-
cation of associations’, we need to elaborate a bit on the subject of confound-
ing. Suppose that the result of a statistical test indicates that HDL levels and
a genetic polymorphism are associated, the two variables being modelled as
two random variables X and Y , and think of a collection of other variables,
such as age, BMI, smoker status, etc., modelled jointly with X and Y as a
random vector Z. For simplicity, assume that Y takes the values 1 and 2 and
that X and Z are discrete. The result of the test indicates that
0 6= ∆ := E[X|Y = 1]− E[X|Y = 2] (2.1)
=
∑
E[X|Y = 1, Z = z]fZ|Y (z|1)− E[X|Y = 2, Z = z]fZ|Y (z|2),
z
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in the usual notation of conditional probability functions and expectations.
If fZ|Y (z|1) = fZ(z) = fZ|Y (z|2) for all z then the result of the test indicates
that
0 < |∆| ≤
∑
z
|E[X|Y = 1, Z = z]− E[X|Y = 2, Z = z]| fZ(z),
hence that |E[X|Y = 1, Z = z]− E[X|Y = 2, Z = z]| > 0 for some z; in
other words, if Z is independent of Y then an association between X and
Y is genuine, at least in the face of Z, in the sense that a difference in the
means of Y in the two groups determined by Y exists within some of the
strata determined by Z. This observation suggests a method of checking
for spurious associations: once evidence in favour of an association between
X and Y has been found, one can examine—graphically, in an exploratory
fashion—the distribution of X across strata determined jointly by Y and Z
and check—by means of post hoc tests—whether the purported association
is visible in at least some of those strata.
It may happen that the association between X and Y has roughly the
same direction and intensity in all strata, in which case Z would not be
confirmed as a confounder. More frequently, however, the association between
X and Y will have the same direction but vary in intensity across the strata
of Z; for instance, if Y is a genetic factor and Z is age, then the effect of Y on
X is expected to weaken with increasing age (cf. p. S19 of Winkelmann et al.
(2000)). In this case it may be concluded that E[X|Y = 1, Z = z]−E[X|Y =
2, Z = z] is a function of z and one will regard Z not only as a confounder but
more specifically as an ‘effect modifier’—the effect subject to modification
being the difference in means of X in the two groups determined by Y .
Less commonly, the effect modification will take the form of an inversion,
E[X|Y = 1, Z = z] − E[X|Y = 2, Z = z] appearing to be positive for z
within one stratum and negative within another (‘Simpson’s paradox’ is a
standard example illustrating the consequences of this situation). Such an
observation will normally need to be strengthened by a plausible biomedical
explanation.
Irrespective of whether E[X|Y = 1, Z = z] − E[X|Y = 2, Z = z] ap-
pears to depend on z or not—irrespective of possible confounders—in any of
the three events just described there are good grounds for declaring the as-
sociation to be genuine. On the other hand, in the event that the association
between X and Y ‘evaporates’ when viewed across the strata determined by
Z—if it appears very weak and to vary randomly in direction, say—then it
seems sensible to assume that E[X|Y = 1, Z = z] = E[X|Y = 2, Z = z] for
all z, and hence, by (2.1), that
10
Statistical Applications in Genetics and Molecular Biology, Vol. 8 [2009], Iss. 1, Art. 7
http://www.bepress.com/sagmb/vol8/iss1/art7
DOI: 10.2202/1544-6115.1420
0 < |∆| ≤
∑
z
∣∣fZ|Y (z|1)− fZ|Y (z|2)∣∣E[∣∣X∣∣ |Y = 1, Z = z];
but since this implies fZ|Y (z|1) 6= fZ|Y (z|2) for some z, we see that a failure
of an association between X and Y to materialize within strata of a putative
confounder Z provides evidence of an association between Z and Y and hence
that Z is a confounder.
Thus, to sum up, the post hoc verification of associations is both a means
of strengthening the evidence in favour of an association and a means of ex-
plaining why an association is likely to be spurious, and any further evidence
derived from it can in principle be incorporated in the ‘map of relationships’
(examples are given at the end of Section 3). Of course, in theory the vector
Z might contain so many possible confounders as to render any post hoc anal-
ysis useless; but in practice one must simply be reconciled with the fact that
an association can only be verified in the face of a few obvious confounders
and that any causal interpretation of the ‘map of relationships’ is tentative.
2.1 The Benjamini-Hochberg method
The Benjamini-Hochberg method is designed to test many, say m, null hy-
potheses simultaneously, of which an unknown proportion γ is true. It con-
sists of computing a set of m test statistics—one for each hypothesis—and
the corresponding set of m p-values (which requires the knowledge of the null
distribution in each case), and then rejecting those null hypotheses whose p-
values fall below a data-dependent threshold. This threshold, given by XRm:m,
where Rm = max
{
i : Xi:m ≤ q im
}
and X1:m, . . . , Xm:m denote the ordered p-
values and q is a number between 0 and 1 chosen by the user, has been
designed so as to keep the expected ratio of the number of incorrect rejec-
tions (or ‘false positives’) to the number of rejections, called false discovery
rate, below q × γ. Since q × γ ≤ q, and since γ is usually unknown in prac-
tice and can be arbitrarily close to 1, what one can generally assert is that
the Benjamini-Hochberg method controls the false discovery rate at q; for this
reason we will refer to q as the conservative (bound on the) false dis-
covery rate. However, in some cases one is able to find an estimate of, or
at least a plausible upper bound for, γ, call it γ¯, and thus make the sharper
statement that the Benjamini-Hochberg method controls the false discovery
rate at q × γ¯. In this form, the method is usually referred to as the adap-
tive Benjamini-Hochberg method, though there are several variants of
it, each based on an estimator of γ¯ (see the subsection below).
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The interpretation of q is somewhat analogous to that of the significance
level in a standard testing procedure, but not quite. What needs to be borne
in mind is that the bigger q, the bigger the number of rejections and the bigger
the number of correct rejections (i.e., the number of false null hypotheses one
successfully identifies); but the bigger q, the bigger the false discovery rate.
The logic of the Benjamini-Hochberg method is to fix the fraction of false
positives among the ‘positive’ results one comes up with at a tolerable level
(dictated by the user), and hope that such level will allow the discovery of
many true positive results.
The Benjamini-Hochberg method is more powerful than traditional mul-
tiple testing methods like the Bonferroni method. Recall that the Bonfer-
roni procedure of level α consists of rejecting those null hypotheses whose
p-values fall below the deterministic threshold α/m, which guarantees that
the chance of unduly rejecting one or more hypotheses is at most α. Intu-
itively, ifm is very large then α/m is very small, which will typically yield very
few rejections (very few ‘discoveries’). In contrast, the threshold provided by
the Benjamini-Hochberg method typically approaches a positive number as
m increases, and therefore yields a sizable set of rejections.
Despite its advantages and general applicability, the Benjamini-
Hochberg also relies on certain assumptions. The control promised by the
method is exact only under certain conditions on the dependence structure
of the sample of p-values. If m is large and γ > 0 (which is the case in
the type of applications we have in mind) then the method will work in the
approximate sense that the false discovery proportion, the ratio of the
number of incorrect rejections to the number of rejections (whose expected
value is the false discovery rate), is bounded above by approximately qγ with
high probability—irrespective of whether the p-values are independent or
not—provided one condition is fulfilled.
To see what this condition is and understand what ‘approximate’ means
we need to introduce some notation. First, let T1, T2, . . . , Tm denote the test
statistics and assume that the test statistics computed under the alternative
hypotheses tend to take smaller values than those computed under the null
hypotheses; in particular, p-values based on unbiased tests are test statistics
with this property. In order to distinguish the test statistics computed under
the null hypotheses from the rest assume that the first m0 = γm ≤ m
statistics are computed under the null and denote them by T ′1, T
′
2, . . . , T
′
m0
.
Finally, assume that T ′1, T
′
2, . . . , T
′
m0
all have the same distribution function,
which we denote by F .3 Typically, the test statistics are the p-values and
F is the uniform distribution function on [0, 1], but in principle F can be
anything and does not even need to be continuous.
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Now consider the multiple testing procedure that consists of rejecting
all the test statistics strictly below a given threshold tm (or, more precisely, of
declaring false all the hypotheses whose statistics are < tm); the Benjamini-
Hochberg method is an example of such a procedure based on the random
threshold XRm:m. By definition, the false discovery proportion incurred by
this procedure is either zero (in case no rejections are made) or equal to
no. of incorrect rejections
total no. of rejections
=
m0
m
1
m0
∑m0
i=1 1[T ′i<tm]
1
m
∑m
i=1 1[Ti<tm]
= γ
Fm(tm−)
Hm(tm−) ,
where 1A denotes as usual the indicator function of the event A (equal to 1
3In practice, the correct calculation of a p-value requires the knowledge of the null
distribution of the test statistic, and with this knowledge one can apply a transformation
to the test statistic in order that its distribution function be (approximately, if the statistic
is discontinuous) equal to F ; hence this last assumption can be met in most situations.
if A occurs, equal to 0 otherwise), Hm is the empirical distribution function
of the test statistics, and Fm and is the empirical distribution function of the
test statistics computed under the null (the first m0). It follows from this
expression that if tm is defined by
4
tm = sup{t : Fm(t) ≤ qHm(t)} (2.2)
then the false discovery proportion is bounded above by qγ. Consequently,
the procedure based on the threshold defined by (2.2) controls the false dis-
covery proportion at q. Moreover, this procedure is optimal among all proce-
dures that consist of rejecting all test statistics below a given threshold and
that make no assumptions about the value of γ, because (i) conditionally on
the q chosen, the higher the threshold the bigger the proportion of correct
rejections, and (ii) increasing the threshold above the tm of (2.2) is impossible
without violating the upper bound qγ on the false discovery proportion.
Unfortunately, the optimal procedure is not realizable in practice be-
cause Fm, unlikeHm, is not observable. However, since each of T
′
1, T
′
2, . . . , T
′
m0
has distribution function F and EFm(t) = F (t) for all t, there is reason to
hope that Fm is relatively close to F and consequently that
t′m = sup{t : F (t) ≤ qHm(t)} (2.3)
is close to the tm of (2.2). If that is the case, then the set of hypotheses de-
clared false by the multiple testing procedure based on t′m will closely coincide
with the set of hypotheses declared false by the multiple testing procedure
based on tm, and the procedure based on t
′
m will not only be close to con-
trolling the false discovery proportion at q but will also be close to being
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optimal among similar procedures. And, as it turns out, the procedure based
on (2.3) is, in essense, the Benjamini-Hochberg method, for it can be shown
that when F is the standard uniform distribution function t′m coincides with
the threshold XRm:m defined earlier.
In conclusion, the condition required for the Benjamini-Hochberg
method to work in an approximate sense is that the empirical distribution
function of the test statistics under the null be close to their common distri-
bution function. And since under very general conditions on the dependence
structure of T ′1, T
′
2, . . . , T
′
m0
Fm converges uniformly to F in probability as
m0 → ∞ (e.g. Ferreira and Zwinderman (2006), Section 3.1), it is correct
to state that when m is large the method works very generally, albeit in an
4If no t satisfies the condition within braces, tm = −∞ and no hypotheses are rejected.
approximate sense. This statement has been amply illustrated by simula-
tion studies based on a wide variety of dependence structures (e.g. Benjamini
et al. (2006), Kim and Wiel (2008), Romano et al. (2008)). As with many
asymptotic results in statistics, however, its generality is also the source of its
weakness, for the adjectives ‘close’ and ‘approximate’ are difficult or impossi-
ble to quantify in actual practice. For this reason, besides invoking arguments
of plausibility as to why the Benjamini-Hochberg method should work in each
case one must also try to check or justify the approximate uniformity of the
empirical distribution of the p-values computed under the null; as will be
seen in Section 3, this can be done using simulation and the data themselves.
2.1.1 Adaptive versions
As explained before, if one can find an estimate or upper bound γ¯ for
the proportion of true null hypotheses then, everything else being in place,
the Benjamini-Hochberg method controls the false discovery rate at q × γ¯,
a more powerful statement than that of the ‘standard’ method. Several
methods of estimating or majorizing γ have been proposed (Benjamini and
Hochberg (2000), Storey and Tibshirani (2003), Storey et al. (2004), Langaas
et al. (2005), Ferreira and Zwinderman (2006), and Benjamini et al. (2006)),
but most of them can be regarded as estimates of the left-hand limit of the
density of the p-values at 1. The ‘overestimator’ of γ we shall use here is
the left-hand limit of the histogram (based on Scott’s rule) of the p-values
at 1. Under general conditions (e.g. Section 4 of Ferreira and Zwinderman
(2006)), this type of overestimator approaches a constant that exceeds γ with
high probability as m increases; consequently, the false discovery proportion
is bounded above by q × γ¯ with high probability for large m, and so is its
expectation, the false discovery rate.
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Of course, in practice one can neither ascertain the validity of the asymp-
totic results nor the accuracy of the desired bound on the actual false dis-
covery rate with the m at hand, and so, ultimately, the application of the
Benjamini-Hochberg method requires a leap of faith (in contrast with Bon-
ferroni’s, for example, which is as reliable as the p-values it is based on).
Simulation studies (e.g. Kim and Wiel (2008), Dudoit et al. (2008)) show
that the estimators of γ and the actual false discovery rate incurred in the
adaptive Benjamini-Hochberg method are generally conservative (as they are
intended to be) under a wide range of data-generating models, and that,
when biased upwards, they do not dramatically exceed their nominal values.
Given the theoretical background and such observations, simple ‘diagnostic’
procedures (see the text around Figure 7 in Subsection 3.2) can help further
to motivate and justify applications of the Benjamini-Hochberg method.
2.2 Discussion
One of the reviewers raised two interesting points about the global control
of the false discovery rate. Since there are at least as many multiple testing
problems as response variables, and since the ultimate aim is to create a ‘map
of relationships’, it may be argued that the control of the false discovery
rate should be imposed on the whole set of tests rather than separately for
each multiple testing problem. Of course, it is undesirable to simply pool
together tests pertaining to different variables (for instance, if one response
variable has more associations with the explanatory variables than another,
then a ‘pooled’ multiple testing procedure will tend to detect only associations
pertaining to the first, and yet the second variable is supposed to be important
in its own right), so it is not appropriate to apply the Benjamini-Hochberg
method to the union of the sets of p-values. Instead, one can compute (as in
the case of the multiple testing problems by strata mentioned in Section 2)
a bound on the ‘global’ false discovery rate as the sum of the bounds on the
individual false discovery rates. Unless there are only a couple of response
variables, however, this procedure will tend to be conservative. Alternatively,
if one is in a position to take the ‘leap of faith’ mentioned in the previous
subsection, one can go for the sharpest approach: If in the multiple testing
problem pertaining to the i-th response variable we reject Ri hypotheses at a
conservative false discovery rate of 0.1, then it can be argued that among the
Ri rejected there are roughly 0.1×Ri false positives, and hence that in total
there are roughly 0.1 ×∑iRi false positives among all the results declared
significant, which of course implies a ‘global’ false discovery rate of 0.1. This
may seem too good to be true, but (as explained in Subsection 2.1) it is
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likely to yield an approximately correct statement under a variety of data-
generating models and even for moderate numbers of hypotheses.5 On the
other hand, it must be recognized that in view of the uncertainties alluded
5Writing Si for the number of incorrect rejections pertaining to the i-th response vari-
able, we see that the ‘global’ false discovery proportion is a random convex linear combi-
nation of the individual false discovery proportions which, asymptotically, is bounded by
a convex linear combination of their individual bounds:
∑
j Sj∑
i Ri
=
∑
j
Sj
Rj
Rj∑
i Ri
<∼ 0.1 with
high probability provided SjRj
<∼ 0.1 for all j with high probability.
to in Subsection 2.1.1 one would often have reservations about claiming such
a bound on the global false discovery rate. All things considered, reporting
the individual conservative false discovery rates per multiple testing problem
is perhaps a fair and transparent procedure; its only disadvantage is that
the more sceptical reader may want to bring down the individual bounds in
order to secure the global bound, and the consequences of doing this can only
be appreciated by examining the lists of rejections and p-values and lopping
parts of the ‘map of relationships’.
The second point concerns the sequential nature of the multiple testing
problems considered at different stages of the analysis: in the third step,
the associations between explanatory variables are restricted to the variables
selected in the second step, so that, for example, choosing a different con-
servative false discovery rate in the second step would change the multiple
testing problem in the third. (By comparison, the transition from the first to
the second step is hardly a problem in this connection, because the selection
of phenotypes is comparable to a decision about which variables to sample
prior to the study.) This raises the question of whether it is appropriate to
bound the false discovery rate separately at each stage, for it is not obvious
that the bound claimed in the third step, which is conditional on the results
of the second, is valid. Furthermore, one may again ask whether report-
ing a ‘global’ false discovery rate would be more appropriate than reporting
the various false discovery rates separately. Unfortunately, there are as yet
no definitive answers to these questions (but see Yekutieli et al. (2006) and
Yekutieli (2008)), so the control of the false discovery rate promised in the
third step is not so easy to justify.
Our best argument supporting the control of the false discovery rate in
a ‘conditional’ multiple testing problem is based on a form of the conditional-
ity principle. Testing the associations between each of the response variables
and the explanatory variables and testing the associations between all the
explanatory variables does not appear problematic in general if one controls
the false discovery rates separately within each multiple testing procedure
(as we have argued above). The difficulty arises when instead of testing
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second multiple testing procedure (irrespective of whether this is based on
Benjamini-Hochberg’s, Bonferroni’s or any other method). This difficulty is
actually quite common; it appears whenever one carries out two statistical
procedures sequentially, the result of the first influencing the set-up (but not
necessarily the conclusion) of the second, and the graceful way out of it is
to invoke the conditionality principle, which in our case would amount to
assuming that the distribution of the tests statistics under the null remains
approximately uniform conditionally on the selection. However ‘obvious’ or
‘intuitive’ the validity of this principle may seem, its application in data anal-
yses is often more a question of faith or philosophy than mathematics, and it
is possible to construct data-generating models that violate it (e.g. Helland
(1995)), so it must be admitted that the control of the false discovery rate (or
indeed of any error rate based on p-values) claimed for the third step should
be taken with reservation. Our feeling is that the conditionality principle
holds approximately in data analyses like the one presented in Section 3.
3 An example: detection of associations be-
tween risk measures of heart disease and
genetic polymorphisms
The REGRESS dataset (Jukema et al. (1995)) consists of measurements of
phenotypic and genotypic variables on 884 male patients suffering from coro-
nary heart disease and having normal to moderately elevated cholesterol lev-
els; according to Maat et al. (1998), it “represents the majority of cardiac
patients seen in clinical practice”. The phenotypic variables include HDL
and LDL cholesterol levels, ‘family history’ (which records whether or not
a patient’s family has a history of heart disease), age, BMI, and other risk
measures of heart disease. The genotypic variables consist of the geno-
types of about 140 single nucleotide polymorphisms (SNPs), each of which
is characterized as ‘wild type’, ‘heterozygote’ or ‘homozygote’ depending on
6A list of the SNPs (with a few question marks) is given in the Appendix; a file with
the REGRESS data can be obtained from A.H. Zwinderman.
the associations between all the explanatory variables one tests the associa-
tions between a selection of explanatory variables, the selection being based
on the first multiple testing procedure: conditionally on the selection, the
tests statistics used to test the association of pairs of explanatory variables
could be biased (the distribution of the p-values under the null might not
be approximately uniform anymore, for example), and consequently bias the
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population of male “cardiac patients seen in clinical practice” in the Nether-
lands or more strictly as the population of patients satisfying the inclusion
criteria set in the REGRESS study.
The phenotypic and genotypic variables considered here have already
been the subject of many association studies; see Winkelmann et al. (2000)
and Kullo and Ding (2007) for reviews and relevant literature One of our
aims is to show that most of the associations established in the literature
can be detected using a simple and robust approach in a single scrutiny of
the REGRESS dataset. The end product of our analysis consists of a ‘map
of relationships’ summarizing the main findings and which will hopefully be
useful in generating working hypotheses and setting up new studies, and
ultimately in helping to pinpoint those gene polymorphisms which influence
the risk of heart disease in similar populations of patients.
The presentation follows the four steps outlined in Section 2.
3.1 Phenotypic variables
We first examine the 20 phenotypic variables that make up most of the base-
line measurements of the REGRESS dataset. Figure 1 shows a dendogram
obtained by clustering the 20 variables by means of an agglomerative hierar-
chical method (implemented in the R routine agnes) where the ‘dissimilarity’
between two variables is given by the tenth root of the p-value of a test of
association between them and the distance between two clusters equals the
average of the dissimilarities between the members of one cluster and the
members of the other. Since the p-values are all based on approximately the
same sample size, their relative closeness to zero should be a good measure
of the strength of the association between two variables; we chose its tenth
root rather than the p-value itself for purposes of visualization.
The variables related to lipids, namely HDL, LDL and total choles-
terol (the sum of HDL, LDL and VLDL (very low density lipoprotein)),
triglycerides, as well as glucose and the variables measuring the amount
of proteins are all measured in mmol/l (millimoles per litre); variables mea-
suring the activity of proteins are measured in µ/ml; levels of apolipopro-
tein(a) and fibrinogen are measured in g/l. CETP (cholesteryl ester trans-
fer protein), apolipoprotein(a) and LPL (lipoprotein lipase) are known to be
involved in the synthesis or metabolism of lipids; fibrinogen and C-reactive
the number—0, 1 or 2—of minor frequency or rare alleles (the alleles that
are less common in the general population).6 Our objective is to detect pos-
sible associations between some of the phenotypic variables and the gene
polymorphisms in a target population that can be roughly defined as the
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part by polymorphisms (in homonymous genes) represented in the REGRESS
dataset. MSD (mean segment diameter) and MOD (minimum obstruction
diameter), measured in mm, are two variables that quantify the diameter
of unobstruction in certain segments of the coronary tree. Stenosis is the
average percentage of constriction over selected blood vessels, and ejection
fraction is the percentage of blood pumped out of the left ventricle per
heartbeat. Finally, systolic and diastolic blood pressures are measured in
mmHg (millimetres of mercury), and BMI in kg/m2.
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Figure 1: Dendogram summarizing the relationships between the 20 phenotypic
variables.
The dendogram provides a simple and sensible picture of the relation-
ships between the phenotypic variables. Since 0.6 in the tenth root scale
corresponds to a p-value of about 0.006, we see that the evidence for the
associations is quite strong. Unsurprisingly, the evidence for associations be-
tween LDL and total cholesterol, HDL and triglycerides, amount of CETP
and activity of CETP, MSD and MOD, and systolic BP and diastolic BP is
particularly strong. There is also good evidence that both HDL and triglyc-
erides are associated with the activity of LPL, the key enzyme involved in the
clearance of triglycerides from plasma. Higher up in the dendogram we find
evidence of the associations between the two groups of lipids headed by LDL
protein are thought to be involved in inflammatory processes associated
with arterial damage. All these proteins are thought to be regulated in
19
Ferreira et al.: An Approach to High-Dimensional Association Studies
Published by Berkeley Electronic Press, 2009
a
ct
iv
ity
 o
f C
ET
P
a
ct
iv
ity
 o
f L
PL ag
e
a
m
o
u
n
t o
f C
ET
P
a
po
lip
op
ro
te
in
(a) BM
I
C−
re
ac
tiv
e 
pr
ot
ei
n
di
as
to
lic
 B
P
e
jec
tio
n f
rac
tio
n
fa
m
ily
 h
ist
or
y
fib
rin
og
en
gl
uc
os
e
H
D
L
LD
L
M
O
D
M
SD
st
en
os
is
sy
st
ol
ic 
BP
to
ta
l c
ho
le
st
er
ol
tri
gl
yc
er
id
es
activity of CETP
activity of LPL
age
amount of CETP
apolipoprotein(a)
BMI
C−reactive protein
diastolic BP
ejection fraction
family history
fibrinogen
glucose
HDL
LDL
MOD
MSD
stenosis
systolic BP
total cholesterol
triglycerides
Figure 2: Two-dimensional colour plot characterizing the direction of the ‘top’
associations—those with p-values below 0.005—between some of the 20 phenotypic
variables: positive associations are represented in green, negative associations in
red.
and HDL and between these and age and BMI; similarly, we find evidence
of the association between MSD/MOD and ejection fraction/stenosis, all of
which are angiographic parameters. High levels of fibrinogen and high activ-
ity of C-reactive protein have each been associated with heart disease; that
they both participate in inflammatory processes and appear to be associated
with each other here does of course not mean that there is a causal relation
between them, and the same applies to all other associations in the graph.
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Figure 2 gives an overview of the sign or direction of the 0.5% ‘top’
associations between the phenotypical variables, as determined by the sign
of the sample correlation coefficient.
Figures 3 and 4 illustrate some of the associations. Despite the strong
evidence in favour of these associations, some of them are rather noisy or even
difficult to distinguish, such as those between LDL and apolipoprotein(a)
levels and between C-reactive protein activity and fibrinogen levels. On the
other hand, it is apparent that some of the variables may serve as proxy
measures of others (e.g. HDL of triglycerides, MSD of MOD, MOD of stenosis,
CETP amount of CETP activity, systolic pressure of diastolic pressure).
The 190 = 20 × 19/2 p-values used to construct the dendogram come
from Spearman tests (in the case of two continuous variables), Kruskal-Wallis
tests (in the case of one continuous variable and one categorical variable), and
chi-square tests (in the case of two categorical variables). Besides family his-
tory of heart disease, the other two categorical variables are systolic BP and
diastolic BP; these variables can only be measured in a very discrete manner,
but they are also sparsely distributed, so in order to test their association we
have categorized them into three classes each: (0, 120], (120, 140], [140,∞)
in the case of systolic BP, (0, 80], (80, 95], [95,∞) in the case of diastolic
BP. All the p-values have been computed with the statistical software R and
are mostly based on approximate or asymptotic distributions, which is al-
right since our interest here is on ranking the associations in terms of their
strength rather than detecting associations at a given false discovery rate.
The histogram of the 190 p-values, shown in the left panel of Figure
5, is typical of multiple testing problems with a proportion of true null
hypotheses, γ (recall Subsection 2.1), substantially smaller than 1: a
roughly decreasing density with a pronounced peak near zero. As mentioned
in Subsection 2.1.1, the height of the histogram near 1 can be taken as an
overestimate of γ; thus the histogram suggests that the number of genuine
associations among the 190 possible associations is quite large, which is
not very surprising.7 The other histogram of Figure 5 was obtained by
simulating the 190 p-values under the assumption that no associations
exist. More precisely, we simulated 17 random samples from normal distri-
butions with the same means and variances as the samples of continuous
phenotypic variables and three random samples from discrete distributions
determined by the frequencies of the categorical variables (all samples being
independently generated and having the same missing values as the real
data) and then carried out the 190 tests and constructed the histogram
of the corresponding p-values. As expected—and in spite of the depen-
dence between the p-values (due to the fact that two p-values can be partly
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Figure 3: Scatter plots illustrating the associations between some of the lipid-
related variables.
based on the same sample)—the histogram of the p-values under the ‘null
hypothesis’ that no associations exist is close to the uniform density.
The objective of this section is really to gain an overall picture of the
phenotypic variables and to choose some of these variables on which to con-
centrate during the rest of the analysis. The main risk measures of heart
disease are cholesterol levels, hypertension, diabetes, family history of heart
disease, BMI, age, and smoking (Winkelmann et al. (2000)), and only the
first four are likely to be strongly influenced by the relatively small set of
genes considered here. It is thus clear that our association study should fo-
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Figure 4: Scatter plots illustrating the associations between some of the angio-
graphic variables, between fibrinogen levels and C-reactive protein activity, be-
tween amount and activity of CETP, and between systolic and diastolic pressure.
cus on lipids (HDL, LDL, triglycerides, etc.), blood pressure, glucose and
family history. Angiographic parameters like MSD, MOD and stenosis are
both measures of heart disease and measures of risk of heart disease, and they
may also be directly or indirectly influenced by genes. In principle, the ac-
tivity and/or amount of proteins like apolipoprotein(a), CETP and LPL are
interesting variables to consider in parallel with lipids, and fibrinogen levels
and C-reactive protein activity are interesting on their own. In view of these
observations, in the remainder of our work we shall concentrate on possible
associations between the more than 130 SNPs represented in the REGRESS
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Figure 5: Histograms of the p-values from 190 tests of pairwise independence
between 20 variables. Left panel: based on the real phenotypic data. Right panel:
based on simulated data under the ‘null hypothesis’ that no associations exist.
7All histograms in this work are constructed with Scott’s rule as implemented in R; with
uniform-like densities, it tends to perfom better than Sturges’s in terms of the L1 norm.
dataset and each of the following eleven phenotypical variables: HDL, LDL,
MSD, systolic BP, glucose, family history, apolipoprotein(a) levels, LPL ac-
tivity, amount of CETP, C-reactive protein activity, and fibrinogen levels.
The reasons for including only one of the blood pressures, only one of the
angiographic measures, and only one of the CETP variables are obvious; the
lack of a clear association between LDL and the levels of apolipoprotein(a)
(see Figure 4), despite the result of the test, seems a good reason for looking
separately at this protein.
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3.2 Associations between phenotypic variables and
polymorphisms
In the second step of our analysis we carry out a multiple testing study
to detect associations between each of the eleven phenotypic variables se-
lected in the previous section and 134 of the polymorphisms included in the
REGRESS dataset (some of the polymorphisms listed in the Appendix have
been excluded because they are present in only one form in this population
of patients). A polymorphism is characterized by 0, 1 or 2—or, in the case
of rarer alleles, by 0 or 1—rare alleles. Whatever the case, a test of inde-
pendence between a phenotypic variable and a given polymorphism amounts
to a test of the hypothesis that the distribution of the former is the same
across the two or three populations determined by the latter. Consequently,
the Scholz and Stephens (1987) test, which is based on empirical distribu-
tions (on ranks, actually) and can be used to test the equality of two or more
populations whose distributions are continuous, and the exact (condition-
ally on the marginal frequencies) chi-square test of independence, seem to be
the ideal tools for our purposes since they are powerful as well as consistent
against all departures from homogeneity/independence.
As mentioned earlier, the main difficulty in performing multiple testing
studies based on non-parametric tests lies in the accurate computation of
p-values. In contrast with the analysis of the preceding subsection, the use
of asymptotic null distributions will not do here because in most cases one
of the populations (e.g. that corresponding to homozygotes) will have very
small numbers. The only solution, therefore, is to compute the p-values by
simulation, which can be a rather demanding task. For example, to compute
(with high probability) a p-value of the Scholz-Stephens statistic correctly
up to four decimal places requires at least 10 million simulation runs, which
can take five days of computing time on a PC with a CPU of 3.20 GHz and
RAM of 2GB. Fortunately, only a few very small or large p-values need to
be computed with this accuracy; the rest can be computed to two decimal
places without affecting the result of the multiple testing procedure.
The p-values of the Scholz-Stephens test presented below were computed
in R with Fritz Scholz’s package adk.test, and they are based on the per-
mutation distribution rather than on the null distribution in order to deal
appropriately with ties. The p-values are generally similar to those estimated
by simulation under the null hypothesis, except in the case of HDL and glu-
cose, whose samples have many ties; in the latter case the data have only one
decimal place and contain only 70 different values, yielding a seriously dis-
torted histogram of p-values calculated assuming no ties. The results based
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Phenotypic Polymorphisms Guess Expected
variable (ranked by p-value) Sign P-value at γ¯ no. false
positives
HDL CETP (-629)C>A + ≈ 0 0.8 1
CETP TaqIB + 0.00001
CETP (-1337)C>T + 0.00040
CETP 784CCC>A + 0.00048
CETP (-2708)G>A + 0.00131
CETP MspI − 0.00172
LIPC (-710)T>C + 0.00212
LPL HIND3 + 0.00455
LIPC (-514)C>T + 0.00948
APOE C112R − 0.00948
LDL None + ... 0.8 ...
MSD ABCA1 InsG141 + 0.00026 ≈ 1 0.07
ABCA1 UTR1395 + 0.00041
LPL Ser447Stop + 0.00404∗ 0.54∗
Systolic BP None ... ... ≈ 1 ...
Glucose LPL Asn291Ser − 0.00006 ≈ 1 0.008
Family history PAI-1 (4G5G) − 0.0027252 ≈ 1 0.36
Apolipoprotein(a) GNβ3 C825T + 0.00435 ≈ 1 0.59
levels NOD2 InsG3020 − 0.00442
LPL activity LPL HIND3 + 0.00080 ≈ 1 0.11
Amount of CETP CETP (-2708)G>A − ≈ 0 ≈ 1 1.73
CETP TaqIB − ≈ 0
CETP MspI + ≈ 0
CETP (-629)C>A − ≈ 0
CETP (-1337)C>T − ≈ 0
CETP 784CCC>A − ≈ 0
CETP (-972)G>A − 0.00029
eNOS G894T − 0.00742
CETP IIe405Val − 0.01288
C-reactive protein APOE C112R − 0.00091 ≈ 1 0.12
activity CETP MspI − 0.00436∗
SCARB1 − 0.00637∗ 0.85∗
Fibrinogen levels None ... ... ≈ 1 ...
Table 1: Results of the multiple testing procedures aimed at detecting associations
between each of 11 phenotypic variables and 134 genetic polymorphisms. The
bounds on the expected numbers of false positives marked by an asterisk refer to
the selection of all polymorphisms indicated; the others refer to the selection of all
polymorphisms indicated except those possibly marked by an asterisk.
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servative estimate of the proportion γ of true null hypotheses (in this case
the proportion of polymorphisms that are truly independent of the relevant
phenotypic variable), which is denoted by γ¯. In most cases, the bound on
the expected number of false positives corresponds to a false discovery rate of
0.10 or less; the case of family history (one rejection at a false disvovery rate
of 0.36) and that of apolipoprotein(a) (two rejections at a false disvovery rate
of 0.28) are exceptions; the other exceptions are indicated by an asterisk. We
shall now explain the results of HDL and LDL in some detail.
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Figure 6: Histograms of the p-values obtained from 134 tests of pairwise indepen-
dence between each of HDL and LDL and 134 polymorphisms.
on the chi-square test—namely those pertaining to systolic BP and family
history—were obtained in R with the routine chisq.test, which estimates
p-values by simulating contingency tables under independence conditionally
on the marginals.
Table 1 summarizes the results of the multiple testing procedures,
namely the 21 polymorphisms that are putatively associated with a pheno-
typic variable, the sign of the association (positive or negative as determined
by the sign of the sample correlation coefficient), the corresponding p-values,
the estimated false discovery rate incurred in each case, and a rough, con-
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as 0.8, or, in other words, that HDL depends on 27 or more polymorphisms.
The ‘top’ (i.e. smaller) 10 p-values of HDL range from nearly 0—
that of the CETP (-629)C>A polymorphism in the CETP gene—to
0.00948—that of APOE C112R. The false discovery rate incurred by
declaring the corresponding polymorphisms to be associated with HDL
is therefore estimated as 0.00948 × 134/10 ≈ 0.127. However, taking
0.8 as an upper bound on γ (the proportion of polymorphisms that are
truly independent of HDL) the false discovery rate can be estimated
somewhat less conservatively as 0.8 × 0.00948 × 134/10 ≈ 0.101, which
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Figure 7: Histograms of p-values resulting from 134 tests of independence be-
tween HDL and the polymorphisms based on two randomly chosen halves of the
REGRESS dataset.
Figure 6 shows the histograms of the p-values obtained from the tests
of independence between each of HDL and LDL and 134 polymorphisms.
The histogram on the left is typical of data with some ‘signal’: a roughly
decreasing function with a peak near zero and going below 1 in the left
neighbourhood of 1. This last feature suggests (recall Subsection 2.1.1) that
the fraction of polymorphisms that are truly independent of HDL is as small
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Figure 8: Histograms of the p-values obtained from tests of association between
each of several phenotypic variables and 134 polymorphisms.
associations. On the other hand, assuming that there could be as many as
27 genuine associations, the 10 selected by the Benjamini-Hochberg method
could represent only about 37% of the ‘discoveries to be made’.
can be interpreted as saying that among the 10 polymorphisms thus
singled out at most one is expected to be spurious. For comparison,
we note that a Bonferroni procedure of level 0.1 would reject the p-values
below 0.000746 = 0.1/134, which would amount to selecting only the top four
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into two subsets of 442 patients and applied the multiple testing procedure on
HDL to each of them. The resulting histograms of p-values, shown in Figure
7, though less peaked near zero than the first histogram in the left panel of
Figure 6 (the tests based on 442 patients being necessarily less powerful than
those based on 884 patients), look roughly similar to each other, especially
near 0 and 1. This suggests that the empirical distribution of the p-values
is more or less invariant with respect to the drawing of samples of the same
size and seems to support the assumption that γ ≤ 0.8.
As seen in the third column of the table, most polymorphisms are pos-
itively associated with HDL, which is to say that the bigger the number of
rare alleles the bigger the levels of HDL tend to be; exceptions are theCETP
MspI andAPOE C112R polymorphisms.
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Figure 9: Histograms of the approximate p-values obtained from 134 tests of
association between each of HDL and LDL and 134 polymorphisms; compare with
the corresponding histograms of Figure 6.
The upper bound of 0.8 on γ we have assumed here should be thought
of as intrinsic to this population of patients and to the variables in question
(HDL and the 134 polymorphisms): it is expected to be more or less insen-
sitive to the particular sample drawn as well as to sample size. To see how
sensible this assumption is, we have randomly split the REGRESS dataset
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In the case of LDL, the histogram of the 134 p-values (Figure 6) deviates
somewhat from the uniform pattern, but roughly in the middle of the [0, 1]
interval rather than near zero. Using the Benjamini-Hochberg method with
varying q we get no rejections for values of q in [0, 0.7], while at q = 0.8 we
suddenly get 40% rejections, which obviously entails an unaffordable number
of false positives. Since the smallest p-value is 0.01957, it is also clear that
no Bonferroni procedure will select a single polymorphism in this case.
Figure 8 shows the histograms of the p-values obtained from the multiple
testing procedures pertaining to the other nine phenotypic variables. The
histograms look rather flat and thus support the basic assumption behind
the Benjamini-Hochberg method: that the empirical distribution of the p-
values computed under the null hypotheses is close to the standard uniform
distribution. Accordingly, the overestimates of γ given in Table 1, obtained by
visual inspection of the histograms of p-values, suggest that HDL and LDL are
the only phenotypes that depend on a substantial number of polymorphisms.
On the other hand, p-values computed with the incorrect null distri-
bution can yield histograms that deviate more seriously from the uniform
density, possibly entailing unreliable bounds on the false discovery rate. To
illustrate this point we have used the adk package to compute approximately
the p-values pertaining to HDL and LDL and compared their histograms,
shown in Figure 9, with those obtained with the correct null distribution:
although the approximate p-values of HDL yield a histogram rather similar
to that of Figure 6, those of LDL suggest a somewhat greater deviation from
uniformity; also, none of the histograms has observations in [0.8, 1].
At this stage we could already visualize the findings listed in Table 1, for
instance by plotting the distribution of the phenotypic variables across the
strata determined by the relevant polymorphisms; however, it will be more
economical to postpone this to the ‘verification stage’ (fourth step) and to
concentrate first on the associations between the selected polymorphisms.
3.3 Associations between selected polymorphisms
Some of the 21 polymorphisms listed in Table 1 may be associated with
each other, and it is obviously of interest to try to detect and illustrate the
associations between them. Some of these associations will not be surprising
and may simply reflect linkage or linkage disequilibrium (like those between
the polymorphisms of the CETP gene), but others may be more interesting.
Our strategy here is to carry out the 210 (21 × 20/2) tests of pairwise
independence between the 21 selected polymorphisms, apply the Benjamini-
Hochberg method to the resulting p-values, and then illustrate the associa-
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tions selected at a given false discovery rate. The test of independence is the
exact chi-square test mentioned at the beginning of the previous subsection.
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Figure 10: Histograms of p-values resulting from 210 chi-square tests of pairwise
independence between the 21 selected polymorphisms: Left panel: based on the
real data. Right panel: based on simulated data under the ‘null hypothesis’ that
no associations exist.
The left panel of Figure 10 shows the histogram of the p-values obtained
from the 210 tests of independence. Its height in the left neighbourhood of 1
suggests that there are relatively few associations between polymorphisms.
In order to check whether the histogram of the p-values computed under
the ‘null hypothesis’ of no associations is approximately uniform, we have
randomly assigned the genotypes of the 21 polymorphisms to the patients
according to the estimated frequencies and carried out the chi-square tests;
the histograms of the resulting samples of p-values, one of which is shown
in the right panel of Figure 10, seem to conform with the expected pattern.
(Given the present sample sizes, the distribution of the p-values of the exact
chi-square tests is virtually continuous, but, again, approximate uniformity
should be checked because the p-values are dependent.)
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Figure 11: Two-dimensional colour plot characterizing the direction of the ‘top’
34 associations singled out at a false discovery rate of 0.10 between the 21 selected
polymorphisms: positive associations are indicated in green, negative associations
in red.
At a conservative false discovery rate of 0.10 we single out the ‘top’ 34
associations with estimated p-values ranging from 0.0000001 to 0.0147131;
thus, among the 34 associations, we may expect three or four to be spurious.
(There is no point in using the adaptive version of the Benjamini-Hochberg
here.) Figure 11 gives an overview of the 34 associations between the
polymorphisms and indicates whether they are positive or not (according to
the sign of the sample correlation coefficient). From the plot we recognize
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Figure 12: Illustration of two associations between polymorphisms of different
genes: histograms of the number of rare alleles in one polymorphism as functions
of the number of rare alleles in another.
four clusters of closely associated polymorphisms corresponding to the same
gene: eigth of the CETP gene, two of ABCA1, two of LIPC and three of LPL.
We note the inverse (or negative) association between CETP MspI and most
of the other polymorphisms of the CETP gene. Interestingly, we only find
evidence of four associations between polymorphisms of different genes: the
associations between CETP MspI and the two ABCA1 polymorphisms, and
between these two and GNβ3 C825T, all of which appear near the bottom
of the list (in ranks 30 to 33), with p-values ≥ 0.0097553. Two of these
associations are illustrated by the histograms of Figure 12: the first is a
positive but apparently weak association, the second an overall negative, not
particularly clear association.
The sets of histograms of Figure 13 illustrate other associations. The
first exhibits a straighforward relationship that typifies the majority of the
associations we have singled out. The second and third exemplify negative,
more or less straightforward relationships. The last one serves to show that
CETP MspI and CETP (-972)G>A, despite having respectively negative and
positive associations with the other CETP genes, have a roughly positive, but
far from straightforward, association with each other.
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Figure 13: Illustration of some of the associations between polymorphisms: his-
tograms of the number of rare alleles in one polymorphism as functions of the
number of rare alleles in another.
3.4 Verification and overview of the findings
The last paragraph is already part of the fourth step and implies that the
associations between the selected genotypes have been verified. Indeed, most
of these associations are straightforward and, after the fact, rather plausible.
In the rest of the paper we shall be concerned with illustrating and verifying
the associations between the phenotypes and the 21 polymorphisms by look-
ing at the distribution of a phenotypic variable within the subpopulations
with and without rare alleles in the relevant polymorphism and across age
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and BMI strata. These are normally regarded as variables one should ‘cor-
rect for’ in epidemiologic studies, and as such they are often used together
with the genotypes as explanatory variables in regression models of pheno-
typic variables as a means of gaining power of detection. Our motivation for
considering them here, however, is that certain combinations of age and BMI
strata are likely to overlie interesting sub-groups of patients which a post
hoc analysis may help uncover and whose identification may subsequently
be useful in drawing up explanations and in planning more refined studies.
For instance, we have already mentioned that the effect of certain genotypes
on indicators of heart disease will be more visible in younger than in older
patients; but one may also anticipate that the effect of others will be visible
mostly in obese individuals. Because this is a rather tedious and lengthy part
of the analysis, we shall examine only HDL and MSD in detail and reproduce
just a few representative graphs; but the relevant information concerning all
the variables will be given at the end in the ‘map or relationships’.
8The value of post hoc p-values lies not so much in the evidence they provide in favour
of an association—which is conditional on having called a result ‘significant’—as in their
capacity to tell us where the association is likely to be present.
HDL appears to be associated with 10 polymorphisms, six of which in
the CETP gene. Overall, the direction of the associations (third column of
Table 1) is consistent across the strata, but, as expected, the hard evidence
in favour of an association usually comes from the more populated strata,
namely those of non-obese—with BMI in (18, 30]—patients; see Figure 14.
Thus, in the case of CETP MspI the evidence is particularly strong in both
young—with age in (30, 55]—and old—with age in [55, 71)—non-obese pa-
tients, and not particularly visible in obese—with BMI in (30, 40]—patients,
judging by the p-values of the Wilcoxon-Mann-Whitney test comparing the
phenotype in the two subpopulations without and with rare alleles, given in
brackets above the boxplots together with the sample sizes.8 Essentially the
same applies to LPL HIND3, except that the association of LPL HIND3 with
HDL in the stratum of young and obese individuals is inverted; according
to the p-value this could be due to chance, but an inversion (relative to the
direction in the other strata) of the association with HDL in this sub-group is
seen in other polymorphisms as well, namely in CETP (-2708)G>A, CETP
(-1337)C>T, CETP 784CCC>A and CETP TaqIB, which could be a useful
observation.
Frequently, an association is visible in only one of the two more pop-
ulated strata: in the CETP (-629)C>A, CETP (-2708)G>A, CETP (-
1337)C>T, CETP 784CCC>A, CETP TaqIB, LIPC (-514)C>T and LIPC
(-710)T>C polymorphisms, for instance, the association is clear in the stra-
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Figure 14: Boxplots of the distribution of HDL by number of rare alleles in the
CETP MspI and LPL HIND3 polymorphisms stratified by age and BMI.
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tum of old and non-obese patients and hardly visible in that of young
and non-obese. However, it can be difficult to say whether this is due to an
imbalance in sample sizes or not. In the case of the CETP (-629)C>A poly-
morphism (Figure 15) we can actually see that this phenomenon cannot be
explained by differences in sample size, because the evidence in favour of an
association with HDL also comes from the small stratum of old and obese
patients, which indeed suggests that the association is particularly strong in
older patients.
Besides CETP (-629)C>A, there is another polymorphism for which
evidence of an association is found in small strata: APOE C112R, whose
association with HDL seems to exist only in young and obese patients (in
young patients at any rate); see Figure 15.
The observations we have made regarding HDL and MSD indicate that
in order to appropriately model (e.g. with a view towards testing hypothe-
ses about relevant parameters) the phenotype as a function of the number
of rare alleles in a polymorphism one may need to use a (regression) model
that accounts for several interactions with age and BMI, since the inten-
sity, and possibly the sign, of the associations may vary according to these
variables. More importantly, they suggest that studies intending to go be-
yond the evidence presented here and to investigate further the role of the
selected polymorphisms should focus on more specific patient populations,
since, for example, some of the genetic variants we have considered seem to
exert an effect on HDL only in the sub-populations of old or of young and
obese patients. The same applies to the other phenotypes.
We turn to the associations between MSD and the polymorphisms
ABCA1 InsG141, ABCA1 UTR1395 and LPL Ser447Stop. The first two
are positively related (see Figure 11), and their positive association with
MSD is very similar, so only that of ABCA1 InsG141 is illustrated in Figure
16. The effect of these ABCA1 polymorphisms on MSD is seen mainly in
the old, non-obese group, but the young, non-obese group also provides
some evidence in the same direction; the inconsistent trends suggested by
the other two strata can be attributed to chance. The second plot in Figure
16 suggests that the association between LPL Ser447Stop and MSD fails to
materialize when viewed against age and BMI. However, by distinguishing
between one and two rare alleles and using the Kruskal-Wallis test we see
some evidence that the association holds in the non-obese group (cf. the
last two plots of Figure 16 with the top ones of Figure 17).
The illustration and verification of the other associations goes on very
much along these lines, and the best way of presenting it and assimilating
it is by means of the map of relationships presented below. Let us just
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Figure 15: Boxplots of the distribution of HDL by number of rare alleles in the
CETP (-629)C>A and APOE C112R polymorphisms stratified by age and BMI.
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mention two more or less special cases: the association between C-reactive
protein activity and SCARB1, and that between family history and PAI-1
(4G5G). The first of these becomes visible—and in the bigger strata—only
if one distinguishes between one and two rare alleles; see Figure 17.
The second, illustrated in Figure 18, is visible in the bigger strata and
consistent in the obese and non obese groups, but it is difficult to interpret:
apparently, the main difference between the group with and without family
history is that the former has fewer individuals with two rare alleles than the
latter. Since the potential number of false positives incurred in this case is
> 1/3 (Table 1), it is probably wise to take this putative association with a
pinch of salt.
The map of relationships presented in Figure 19 provides an overview of
the findings of our association study and includes several observations gained
at the verification stage. In this diagram, positive associations are symbol-
ized by green edges connecting the variables (phenotypes or genotypes) and
negative associations by red edges. ‘Weak edges’, indicated by green or red
dotted lines, represent associations thought to hold in a wide sense: for in-
stance, CETP lle405Val seems to be negatively associated with most of the
five CETP polymorphisms listed in the box immediately below it, but in
our study we have not actually declared it to be associated with CETP (-
1337)C>T. In contrast, CETP MspI is linked to the box of those same five
CETP polymorphisms by a ‘strong edge’ because it has been declared asso-
ciated with all of them. Variables placed within green or red boxes indicate
variables declared to be associated; for example, the five CETP polymor-
phisms we have been referring to are all thought to be positively associated
with each other. (‘Weak boxes’, outlined by dotted rather than full lines, may
be used in a wide sense for the same purpose, but we do not require them in
the present diagram.) In contrast, CETP lle405Val and CETP (-972)G>A,
not having been declared associated, are placed within a black box. Age
and BMI do not appear in the diagram, though as we have seen they affect
the associations between the polymorphisms and other phenotypes. Other
phenotypes such as MOD (obviously related to MSD) and activity of CETP
(related with amount of CETP) also do not appear. Finally, some of the
edges are supplemented with legends containing post hoc information, such
as a question mark reminding us of the caveat about the putative association
between family history and PAI-1 (4G5G), or an indication about the age
and BMI subgroups in which the corresponding associations are thought to
be particularly strong. As examples of the latter, we mention the two CETP
polymorphisms in the top left corner, which are thought to be associated
with the amount of CETP in younger patients (no real evidence having been
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Figure 16: Boxplots of the distribution of MSD by number of rare alleles in the
ABCA1 InsG141 and LPL Ser447Stop polymorphisms stratified by age and BMI.
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Figure 17: Boxplots of the distributions of MSD and C-reactive protein activity
by number of rare alleles in the LPL Ser447Stop and SCARB1 polymorphisms,
respectively, in the bigger strata of BMI and age. (For the sake of visualization,
some outliers have been omitted in the plots of C-reactive protein activity.)
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Figure 18: Histograms of the distribution of the number of rare alleles in the
PAI-1 (4G5G) polymorphism stratified by age and BMI.
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Figure 19: Map of relationships summarizing the main findings of the present
association study: positive associations are indicated in green, negative associations
in red.
found in older patients), and the five CETP polymorphisms just below them,
which seem to be associated with the phenotype especially (but not only)
in young patients. The question and exclamation marks accompanying the
links between polymorphisms of different genes (e.g. CETP MspI and the
two ABCA1 polymorphisms) reflect the fact that besides being among the
weakest in terms of p-values these associations are also the only unexpected
ones from a biological point of view, which makes them likely candidates for
false positives (though biologically there is no a priori reason to rule them
out).
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Figure 20: Map of relationships summarizing the associations between the CETP
polymorphisms. The outlines in black and blue identify the subsets of polymor-
phisms putatively associated with HDL and amount of CETP.
For simplicity, the relationships between the CETP genes have not been
fully represented in Figure 19, but they can be further visualized in Figure 20.
There is a core of five polymorphisms positively associated with each other,
positively associated with HDL, and negatively associated with amount of
CETP. These five polymorphisms are in turn all negatively associated with
CETP MspI, whose associations with HDL and CETP amount are, accord-
ingly, negative and positive. This suggests that the six polymorphisms in the
intersection of the black and blue outlines of Figure 20 function essentially
as a unit regarding the two phenotypes. The remaining three polymorphisms
probably deserve to be considered separately—for instance, CETP IIe405Val
seems to be negatively associated withCETP MspI and positively associated
with some of the ‘core’ CETP polymorphisms, andCETP (-972)G>A seems
to be positively associated with both CETP MspI and the core five—and
could perhaps help explaining why the effect of the CETP polymorphisms on
CETP amount is greater in younger patients while their effect on HDL is, if
anything, more visible in older patients.
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Figure 21: Boxplots of the distribution of CETP amount by ‘CETP profile’.
Figure 20 prompts the question of whether anything can be learned
from looking at the joint effect of polymorphisms on a phenotype. At this
‘post post hoc’ stage there is probably very little new, solid information to
be gained, and saying something substantial about how genetic interactions
influence a given phenotype will certainly require data based on new, more
refined studies. Nevertheless, for illustration purposes we shall finish our
analysis by trying to extract something about the behaviour of amount of
CETP as a function of a ‘joint CETP profile’.
Taking into account what our diagrams say about the CETP polymor-
phisms and their associations with CETP amount, it seems sensible to create
a CETP profile based on the eight polymorphisms contained in the blue out-
line of Figure 20 and to reduce the information on the core five polymorphisms
CETP (-629)G>A, TaqIB, 784CCC>A, (-1337)C>T and (-2708)G>A to a
single variable. We shall therefore say that there is a ‘mutation’ in the core
five polymorphisms if there is at least one rare allele in one of them, and
to further simplify matters that there is a ‘mutation’ in each of the other
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three polymorphisms if there is at least one rare allele. Thus, indicating the
existence of no rare alleles by 0 and the existence of rare alleles by 1, a profile
will be represented by a string like 0100, where the first digit corresponds to
the core five and the remaining to CETP MspI, (-972)G>A and IIe405Val,
in this order. Figure 21 shows boxplots of the distribution of CETP amount
as a function of the CETP profile thus created. The horizontal line is at the
height of the median of the group with no mutations and may serve as a
reference with which to compare the other groups. Going from left to right,
we see once more that rare alleles in (-972)G>A and IIe405Val decrease the
amount of CETP; rare alleles in MspI increase it; the increase in the pheno-
type ‘due to’ rare alleles in MspI is tempered by rare alleles in (-972)G>A
and IIe405Val; two or three rare alleles occurring simultaneously in the core,
(-972)G>A and IIe405Val polymorphisms seem to cause a bigger decrease
in the amount of CETP, but even in such cases a rare allele in CETP MspI
brings the levels of the phenotype close to ‘normal’.
3.5 Discussion of the findings
Most of the associations between the 21 polymorphisms listed in Table 1 and
various phenotypes have been studied by many authors and in particular by
the authors of the Regress study. Associations between the CETP gene vari-
ants, CETP activity and HDL cholesterol have been observed in a previous
analysis of the Regress data (Klerkx et al. (2003)) and in many others as
well (e.g. Drayna and Lawn (1987), Funke et al. (1994), Bruce et al. (1998),
Yamashita et al. (2000)). Consequently, several CETP-inhibitors have been
developed for treatment of patients with low HDL cholesterol; recently one of
these inhibitors was shown to be very effective in increasing HDL cholesterol
but was also associated with increased mortality (Barter et al. (2007)). In a
further analysis of the Regress data, Boekholdt et al. (2006) considered the
association of HDL cholesterol with genetic variation in seven genes involved
in reverse cholesterol transport. In addition to associations with the CETP
gene, they found weak associations with markers in the lipoprotein lipase
(LPL) and the scavenger receptor (SCARB1) genes but not with the hepatic
lipase gene (LIPC), which we have singled out here. Indeed, when testing
the association between HDL and LIPC (-514)C>T by means of analysis of
variance they considered only the 546 individuals with no missing values in
any of a given set of 14 polymorphisms rather than the group of 799 individ-
uals with no missing values in HDL and LIPC (-514)C>T, and consequently
obtained a p-value of 0.10 in place of the ‘legitimate’ p-value of 0.006, which
is close to the one we got with the Scholz-Stephens test. This exemplifies
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well one disadvantage of the regression approach to the detection of asso-
ciations, for it was with the purpose of fitting a regression model to HDL
as a function of the number of rare alleles that Boekholdt et al. (2006) dis-
carded 32% of useful (as far as HDL and LIPC (-514)C>T are concerned)
data. The APOE gene has been associated with LDL cholesterol many times
but also with HDL cholesterol, either directly or via the association between
HDL and LDL cholesterol (Burman et al. (2008)). Surprisingly, LDL choles-
terol levels were not found to be associated with any genetic marker in the
present analysis, while their heritability is thought to be high (O’Connell et
al. (2005)) and several genes are known to influence LDL cholesterol’s expres-
sion. Our study, however, includes only male patients with total cholesterol
levels between 4 and 8 mmol/L, and we suspect that this selection severely
limits LDL cholesterol variation and therefore the power of finding associa-
tions with genetic markers. Also surprising is the lack of association between
systolic blood pressure and genetic variants, while many genes (for instance
in the RAS system; see Dahlo¨f (2008)) have been described as influencing
blood pressure. Apoliproprotein(a) levels are known to be very highly reg-
ulated by genetic variants in the LPA gene on locus 6q27; heritability of
Apo(a) is thought to be high and mostly explained by this locus (Hasst-
edt et al. (1983)). Recently, several genome wide linkage studies (Lo`pez et
al. (2008)) identified several loci also influencing apo(a) among which are
loci involved in the tissue factor pathway; GNβ3 and NOD2, however, have
not been associated with Apo(a) before. Associations between inflammatory
and thrombotic markers such as C-reactive protein and fibrinogen and serum
lipids such as HDL and LDL cholesterol have been observed by many authors
(Abou-Raya et al. (2007), Alber et al. (2008), and references therein). Asso-
ciations between extent/severity of coronary artery disease and the markers
listed in Table 1 have been studied by many authors. Hundreds of associa-
tion studies with candidate genes (among which are APOE, LIPC, PPARG,
TNF, PECAM, ABCA1, LPL) have been reported, but few have been con-
vincingly confirmed. Possible explanations for this include publication bias,
ethnic admixture, and small sample sizes. Genome-wide linkage studies have
mapped several loci that may affect susceptibility to coronary artery dis-
ease/myocardial infarction (Watkins and Farrall (2006)), though only in two
studies has the likely gene been identified (Helgadottir et al. (2004, 2006)).
Association studies have identified several plausible genetic variants affecting
lipids, thrombosis, inflammation or vascular biology, but for the most part
the evidence is not yet conclusive (Watkins and Farrall (2006)). Recently,
the Wellcome trust case-control consortium (and others) performed genome
wide association analyses that did not find strong evidence for any of the
candidate genes (Wellcome Trust Case Control Consortium (2007)).
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4 Discussion
The fact that we have singled out most of the polymorphisms that crop up in
the literature in connection with heart disease, and even a couple of new ones,
in a single scrutiny of the REGRESS dataset suggests that our approach,
despite its emphasis on validity, can be powerful. Whether it is generally
more or less powerful than other methods is a legitimate but futile question:
for instance, comparing our method with some sort of parametric version
of it will yield a whole range of different conclusions concerning detection
power and control of the false discovery rate; this is obvious from the point
of view of simulation, as one can vary the data generating model from the
situation where the assumptions required by the parametric methods are
fullfilled in all perfection to situations where they are grossly violated, and
it is equally obvious from the point of view of real data, as different datasets
will be compatible with the assumptions to a different degree and the truth
about a dataset cannot really be ascertained.9 The reasons why ours may be
preferable to the usual approaches to association studies have been given in
Section 2; they have mainly to do with transparency and with the need for
clamping down on false positive results.
The verification and overview of the findings presented in Subsection
3.4, which culminates in the drawing up of the map of relationships, is an
important part of our association study. Ideally, it should help biomedical
researchers in elucidating the mechanisms of a disease—or at least in refor-
mulating questions and setting up more specific studies with a view towards
9It may be worth elaborating: If method A yields more ‘discoveries’ than method B at
the same conservative false discovery rate on a given real dataset, this does not necessarily
mean that A is better than B on that dataset, because on the one hand it is difficult to tell
which discoveries are genuine and on the other hand method A may entail an actual false
discovery well above that of B, which would explain the apparent difference in power.
elucidating the mechanisms of a disease. The impression we have from read-
ing the literature is that association studies—and we mean those addressed to
biomedical audiences in the first place—tend to stop where statistical meth-
ods stop, namely at the point where a list of significant results is presented
and observations are made about some of the significant results having been
called significant by other studies, very much like in our discussion of the
findings in Subsection 3.5. Compounded by Rees’s (2002) opinion that “it is
the geneticists and biochemists who need to learn some medicine”, this would
suggest that a lot more time and effort should be invested by both generalists
and specialists in pure biomedical thinking going beyond the list of significant
results. Our hope is that maps of relationships based on robust methods like
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that of Figure 19 will provide not only reliable and digestible summaries of
statistical results but also ground for thorough, properly biomedical investi-
gations.
It must be recognized, however, that the feasibility of a map of relation-
ships depends very much on the problem and dataset at hand. For example,
it is doubtful whether the results of a study involving thousands or tens of
thousands of ‘genes’ could be summarized by a couple of diagrams without
some sort of downscaling procedure. In principle, the first three steps of our
approach can cope with any number of explanatory variables, but the fourth
step (‘verification and overview’) would definitely need to be expanded to
deal with cases where the number of associations declared significant is in
the order of hundreds or thousands.
Appendix: List of gene polymorphisms
No. Name in SAS file Gene name Abbreviation Polymorphism
1 AA1 83 Apolipoprotein A1 APOA1 C83T
2 AA1 M75 APOA1 (-75)G>A
3 AA4 347 Apolipoprotein A4 APOA4 Thr347Ser
4 AA4 360 APOA4 Gln360His
5 AA5 pol1 Apolipoprotein A5 APOA5 (-1131)T>C
6 AA5 S19W APOA5 Ser19Trp
7 AAT 213 Protein inhibitor PI V213A
8 AAT TAQI PI G1237A?
9 AB 3500 Apolipoprotein B APOB Arg3500Gln
10 AB 71 APOB Thr71Ile
11 ABC 1051 ATP-binding cassette transport protein A1 ABCA1 G1051A
12 ABC 1252 ABCA1 (-1252)G>A
13 ABC 1320 ABCA1 ?
14 ABC 1395 ABCA1 (-1395)C>T
15 ABC 141 ABCA1 ?
16 ABC 1591 ABCA1 T1591C
17 ABC 1699 ABCA1 ?
18 ABC 17 ABCA1 C17G
19 ABC 191 ABCA1 (-191)G>C
20 ABC 217 ABCA1 ?
21 ABC 2706 ABCA1 G2706A
22 ABC 2715 ABCA1 A2715C
23 ABC 2723 ABCA1 G2723C
24 ABC 2868 ABCA1 G2868A
25 ABC 3044 ABCA1 A3044G
26 ABC 3911 ABCA1 G3911C
27 ABC 5155 ABCA1 G5155A
28 ABC 518 ABCA1 ?
29 ABC 5587 ABCA1 C5587G
30 ABC 6844 ABCA1 C6844T
31 ABC 69 ABCA1 C69T
32 ABC 877 ABCA1 Ala877Val
33 ABC M477 ABCA1 (-477)C>T
34 AC3 1100 Apolipoprotein C3 APOC3 C1100T
35 AC3 3175 APOC3 C3175G, SstI
36 AC3 3206 APOC3 T3206G
37 AC3 M455 APOC3 (-455)T>C
38 AC3 M482 APOC3 C(-482)T
39 AC3 M641 APOC3 (-641)C>A
40 ACE Angiotensin I converting enzyme ACE Ins287 bp Alu
repeat sequence
41 AD1 460 Adducin 1 ADD1 G460W
42 AE 112 Apolipoprotein E APOE Cys112Arg
43 AE 158 APOE Arg158Cys
44 ANG 174 Angiotensinogen AGT T174M
45 ANG 235 AGT M235T
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46 ANP 2238 Natriuretic Peptide Precursor A NPPA T2238C
47 ANP 7 NPPA V7M
48 AR2 16 Beta-2-adrenergic receptor ADRB2 R16G
49 AR2 27 ADRB2 Q27E
50 AR3 64 Beta-2-adrenergic receptor ADRB3 W64R
51 ATI 1166 Angiotensin II receptor type 1 (ATII) AGTR1 A1166C
52 BN 648 Unknown HDL modifier gene BRUNHAM A648G
53 BN 726 BRUNHAM C726A
54 C 2 Cholesterol ester transport protein CETP G1A
55 C 405 CETP Ile405Val
56 C 442 CETP Asp442Gly
57 C 784 CETP CCC784A
58 C ECONI CETP ECONI
59 C M1337 CETP (-1337)C>T
60 C M1614 CETP A6-1614A7
61 C M1632 CETP A6-1632A5
62 C M1653 CETP (-1653)T>C
63 C M1673 CETP (-1673)T>C
64 C M1932 CETP (-1932)T>C
65 C M2708 CETP (-2708)G>A
66 C M629 CETP (-629)C>A
67 C M630 CETP (-630)C>A
68 C M827 CETP (-827)C>T
69 C M875 CETP (-875)C>T
70 C M972 CETP (-972)G>A
71 C MSPI CETP MspI
72 C TAQIA CETP TAQIA
73 C TAQIB CETP TAQIB
74 CBS 833 Cystathionine synthase CBS T833C (I278T)
75 CBS INS CBS 844ins68
76 CD M159 CD14 lipopolysaccharides receptor CD14 (-159)T>C
77 Cyp7 Cholesterol 7-alpha-hydroxylase CYP7A1 A278C
78 ENO 894 Endothelial Nitric Oxide Synthase eNOS G894T
79 ENO M690 eNOS (-690)C>T
80 ENO M786 eNOS (-786)T>C
81 ENO M922 eNOS (-922)A>G ((-948)A>G?)
82 ENO VNTR eNOS VNTR
83 F2 20210 Blood coagulation factor II (prothrombin) F2 G20210A
84 F5 506 Blood coagulation factor V F5 G1691A / Q506R
85 F7 10976 Blood coagulation factor VII F7 G10976A
86 F7 10B F7 10-BP INS, NT-323?
87 FGA TAQI Fibrinogen a FGA TAQI
88 FGB M455 Fibrinogen FGB (-455)G>A
89 GN3 825 Guanine Nucleotide-binding protein, beta-3 GNB3 C825T
90 GP3 1565 Glycoprotein IIIa GP IIIa T1565C
(Human platelet (allo)antigen, HPA)
91 GPI 807 Glycoprotein Ia GP Ia C807T
92 GPI 873 GP Ia G873A
93 HL M514 Hepatic lipase LIPC (-514)C>T
94 HL M710 LIPC (-710)T>C
95 HL RFL19 LIPC RFLP1?
96 HL RFL20 LIPC RFPL2?
97 IC 214 Intercellular adhesion molecule 1 ICAM1 ?
98 LC 208 Lecithin-cholesterol acyltransferase LCAT Ser208Thr
99 LD 1170 LDL receptor gene LDLR ?
100 LD 1959 LDLR C1959T
101 LD NCOI LDLR NCOI
102 LD TAQI LDLR TAQI
103 LP 291 Lipoprotein lipase LPL Asn291Ser
104 LP 447 LPL Ser447Stop
105 LP 9 LPL Asp9Asn
106 LP HIND3 LPL HIND3
107 LP M93 LPL (-93)T>G
108 LP PVUI LPL PVUI
109 LPA 121 Lipoprotein A, Lp(a) LPA G121A
110 LPA 93 LPA C93T
111 LTA 26 Lymphotoxin-Alpha LTA Thr26Asn
112 MP COMB ? ? ?
113 MP3 STRO Matrix metalloproteinase 3 MMP3 ?
114 MP9 MMP9 Matrix metalloproteinase 9 (Gelatinase B) MMP9 ?
115 MT 677 Methylenetetrahydrofolate reductase MTHFR C677T
116 MTP 493 Microsomal triglyceride transfer protein MTP (-493)G>T
117 NOD 3020 Nucleotide-binding NOD2 3020InsC
oligomerization domain protein 2
118 NOD 908 NOD2 G908R
119 NOD Unkn NOD2 ?
120 PA 11053 Plasminogen Activator Inhibitor 1 PAI1 G11053T
121 PA 4g5g PAI1 4G5G
122 PEC 125 Platelet/endothelial cell adhesion PECAM1 Leu125Val
molecule (CD31 antigen)
No. Name in SAS file Gene name Abbreviation Polymorphism
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123 PEC 53 PECAM1 G53A
124 PEC 670 PECAM1 R670G
125 PON 192 Paraoxonase I PON1 Gln192Arg
126 PON 55 PON1 Leu55Met
127 PON2 311 Paraoxonase II PON2 Ser311Cys
128 PPA 162 Peroxisome proliferative activated PPARa Leu162Val
receptor α
129 PPA 3 PPARa G2176A
130 PPG 12 Peroxisome proliferative activated PPARg Pro12Ala
receptor gamma
131 SCA 493 SODIUM CHANNEL, NONVOLTAGE- SCNN1A W493R
-GATED 1, ALPHA SUBUNIT SCNN1A
132 SCA 663 SCNN1A ?
133 SE 128 Selectin E SELE S128R
134 SE 554 SELE Leu554Phe
135 SOD 213 Superoxide Dismutase (extracellular) SOD3 Arg213Gly
136 SRB1 E1 Scavenger Receptor class B type 1 SRB1 Gly2Ser
137 SRB1 E8 SRB1 C1050T
138 SRB1 I5 SRB1 Intron 5 C/T
139 TL4 299 Toll-like receptor type 4 TLR4 D299G
140 TL4 399 TLR4 T399I
141 TNF M238 Tumor necrosis factor alpha TNFa (-238)G>A
142 TNF M244 TNFa ?
143 TNF M308 TNFa (-308)G>A
144 TNF M376 TNFa (-376)G>A
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